An estimated 128.5 million people are expected to be presbyopic in the United States by 2023.
Both established industry players and clinical-stage companies are increasingly focused on expanding presbyopia treatment options, with the hope of improving patient satisfaction in this important demographic group.
The COVID-19 pandemic has made wearing reading glasses even more problematic due to fogging of glasses while wearing masks, further highlighting for patients the value of a pharmacologic treatment for presbyopia that could reduce their dependence on glasses.
We all have many patients with
Uncategorized